One study in melanoma patients showed that the depletion of all B-lineage cells by anti-CD20 immunotherapy reduced tumor-associated inflammation and CD8+ T-cell numbers, while a higher frequency of plasmablasts in pretherapy melanomas predicted a better response to and survival following ICB therapy [113]. This evidence concerns the gene CD8A and melanoma.